$YMTX

Yumanity Therapeutics Inc

  • NASDAQ

PRICE

$1.675 ▲0.299%

Last Close

VOLUME

24,382

DAY RANGE

1.63 - 1.68

52 WEEK

0.95 - 13.9

Join Discuss about YMTX with like-minded investors

profile
@maletone #StockTraders.NET
recently

$YMTX, $AERC, $RDBX, $GOVX, $SIGA, $ARRY, $DIDi, $EFOI

49 Replies 8 👍 15 🔥

profile
@maletone #StockTraders.NET
recently

$YMTX feels like it will fade lower

69 Replies 14 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

was hoping $YMTX was going to go to 2.30's

65 Replies 11 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

watching $ymtx for higher

68 Replies 6 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

short small $YMTX but still expect games and want it higher

103 Replies 14 👍 11 🔥

SO
@soheil.n #StockTraders.NET
recently

these are you long watch list? > @maletone said: $YMTX, $ARRY, $DIDI, $HUSA along with what you posted

119 Replies 10 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

$YMTX, $ARRY, $DIDI, $HUSA along with what you posted

43 Replies 7 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

Tim oconnell is pumping $YMTX

131 Replies 13 👍 13 🔥

Key Metrics

Market Cap

17.80 M

Beta

1.33

Avg. Volume

44.94 K

Shares Outstanding

10.86 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-03

Next Dividend Date

Company Information

Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

CEO: Meenu Chhabra

Website:

HQ: 80 Guest St Fl 5 Boston, 02135-2071 Massachusetts

Related News